The abstract is read at the publisher; the summary is JClub's.
EGFR P-loop/αC-helix compressing (PACC) mutations and exon 20 insertions (ex20ins) form distinct kinase-domain subsets with reduced sensitivity to EGFR TKIs for classical sensitizing mutations.
- Why it matters: The gap is that these EGFR alterations are structurally defined yet treated with regimens designed for classical mutations, despite evidence of weaker TKI responses and frequent chemotherapy use.
- What they did: This narrative review synthesizes structural biology, clinical trial results, and real-world evidence to compare current therapies, resistance mechanisms, and potential sequencing for PACC and ex20ins.
- The result: Second-generation TKIs like afatinib show the most consistent activity for PACC variants (G719X, S768I, E709X, L747X), while common-plus-PACC compound mutations often benefit more from third-generation TKIs such as osimertinib; for ex20ins, amivantamab and mutant-selective TKIs (including sunvozertinib) show clinically meaningful activity, with WU-KONG28 reporting first-line superiority of sunvozertinib over platinum-pemetrexed.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.